EntreMed’s pipeline contains a portfolio of three clinical-stage product candidates. All of the product candidates are orally-administered compounds that have demonstrated potential in oncology and inflammatory diseases. In addition to our oncology drug candidates, we have a Phase 1 candidate, Panzem®, for the treatment of rheumatoid arthritis.

The Company’s priority program, ENMD-2076, is currently in multiple Phase 1 oncology studies. Although our other clinical product candidates (MKC-1 and ENMD-1198) continue to be in various stages of Phase 1 and 2 oncology studies, we do not intend to initiate additional new studies for these programs unless additional significant financing becomes available to us and we have completed the clinical data set from current active studies. This reprioritization allows us to redirect the majority of our resources to the clinical development of ENMD-2076.

EntreMed’s Pipeline

EntreMed’s pipeline offers promising and unique product candidates for development and commercialization for the following reasons:

Multiple Mechanisms of Action
Diseases such as cancer employ multiple strategies to survive involving various cellular signaling pathways that promote their transformation and growth. Cancer cells can rapidly evade drugs that are highly specific for a target within one of these pathways through the development of resistance mechanisms. If more than one of these redundant signaling pathways can be interrupted at once, then the chance for resistance to develop is greatly reduced. EntreMed’s drug candidates act by attacking cancer cells through multiple pathways that promote the formation and replication of tumor cells, while also interrupting the formation of blood vessels that nourish and sustain tumor growth. EntreMed has pursued oncology indications that could provide proof-of-concept data to support the design of pivotal trials.

Versatility
While the Company’s clinical efforts continue to focus on oncology, EntreMed believes that other diseases where angiogenesis plays a role in pathology represent future opportunities.

Convenient Dosing
EntreMed is developing drug candidates that will be easy to use as compared to other modes of drug administration. The Company is focusing specifically on drugs that can be administered orally.

Intellectual Property Position
All EntreMed pipeline programs are backed by strong intellectual property rights. Each product candidate is covered by issued or pending composition, method and use patents. The Company owns or has licensed over 60 patent applications and issued patents in the United States for our product candidates. The Company has well over 100 pending patent applications and issued patents in the United States and other countries.